Aclaris bags St. Louis biotech for $20M; Pfizer investing $100M in gene therapy work
→ The Pfizer vets at Confluence Life Sciences have agreed to be bought out by Aclaris $ACRS in a deal that comes with
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
